National Science Foundation

The University of Washington is a prominent educational institution located in Seattle, Washington, founded in 1861. It offers a diverse range of undergraduate, graduate, and research programs across various fields, including business, social sciences, science, law, medicine, and public affairs. The university comprises several specialized schools, such as the College of Engineering, School of Dentistry, School of Pharmacy, School of Public Health and Community Medicine, School of Business, School of Humanities and Sciences, School of Law, School of Nursing, and College of Ocean and Fishery Sciences. In addition to its academic offerings, the university is dedicated to fostering innovation through CoMotion, which provides resources and support to help researchers and students translate their ideas into tangible societal and economic benefits.

The University of Washington is a prominent educational institution located in Seattle, Washington, founded in 1861. It offers a diverse range of undergraduate, graduate, and research programs across various fields, including business, social sciences, science, law, medicine, and public affairs. The university comprises several specialized schools, such as the College of Engineering, School of Dentistry, School of Pharmacy, School of Public Health and Community Medicine, School of Business, School of Humanities and Sciences, School of Law, School of Nursing, and College of Ocean and Fishery Sciences. In addition to its academic offerings, the university is dedicated to fostering innovation through CoMotion, which provides resources and support to help researchers and students translate their ideas into tangible societal and economic benefits.

Transparent Path is a logistics technology company focused on enhancing supply chain visibility for perishable goods, addressing issues of waste, cost, and risk. Founded in 2018 and restructured as a social purpose corporation in 2020, the company combines advanced technologies such as AI, IoT, and machine vision to modernize outdated supply chain practices. Their flagship product, the Transparent Path Visibility Platform, utilizes cellular sensors affixed to pallets, providing real-time data on location and environmental conditions to prevent spoilage and ensure product safety. Additional offerings include FreshScore, a predictive freshness algorithm that helps optimize product routing, and ProofScore, an algorithm that evaluates transparency in supply chains. These innovations not only help reduce operational losses but also promote environmental sustainability by minimizing waste. Transparent Path serves a diverse clientele, including sectors such as food, pharmaceuticals, and construction chemicals, and has established partnerships with notable organizations like Intel and ReFED. The company is actively working towards scaling its operations and expanding its offerings.

Senseer Health, founded in 2017, focuses on addressing the chronic disease market by developing Smart Medical Device Therapies for managing various chronic conditions, which affect a significant portion of older adults. The company's innovations began with patented microsensors that monitor implantable devices for patients with hydrocephalus, renal, and cardiovascular diseases. To enhance the effectiveness of these microsensor-enabled devices, Senseer has incorporated advanced wearable and ambient sensor technologies. The integration of these multi-modal sensor technologies with an IoT software platform allows for the utilization of proprietary data sets and predictive analytics. This comprehensive approach provides healthcare providers with tools for remote monitoring and timely interventions, ultimately aiming to improve the quality of life for individuals with chronic conditions while reducing costs and enhancing patient safety.

Claria Medical is a pre-commercial medical device start-up focused on developing innovative solutions for women's healthcare, specifically targeting unmet needs in gynecologic surgery. The company specializes in creating minimally invasive surgical tools designed to enhance procedures such as hysterectomy and myomectomy. Claria Medical has received recognition for its early achievements, including a “Safer Technologies Designation” from the U.S. Food and Drug Administration. Additionally, the company has secured funding through private investments as well as grants from the National Science Foundation and the National Institutes of Health to support its product development efforts. By providing specialized surgical assistance, Claria Medical aims to improve outcomes for women undergoing these procedures.

Tiny Cargo specializes in a unique drug delivery system utilizing non-immunogenic bovine milk-derived exosomes. This innovative approach allows for the effective oral or intravenous administration of potent therapeutics. The company focuses on delivering treatments for various serious health conditions, including ischemic heart disease, gastrointestinal radiation disease, and glioblastoma multiforme, among others. By leveraging its technology, Tiny Cargo aims to enhance the delivery of peptide drugs, making it applicable to a wide range of current peptide therapeutics and improving patient outcomes in the treatment of neurological and other pathologies.

QSimulate is a Boston-based company that develops cloud-based quantitative simulation tools aimed at addressing complex challenges in the chemical and pharmaceutical industries. By harnessing the principles of quantum mechanics, QSimulate’s platform facilitates quantum molecular simulations, allowing clients to tackle industrial-scale problems more effectively. The tools offered by the company automate workflows, relieving computational scientists of routine tasks and thereby increasing productivity. This innovation enables organizations to accelerate their research and development processes, ultimately enhancing their capacity to innovate and solve critical issues in their fields.

Simmbion specializes in innovative therapeutic solutions by utilizing symbionts to manufacture therapeutic agents directly within the human body, effectively transforming it into a living pharmacy. This technology aims to eliminate the challenges associated with traditional therapy manufacturing, such as the need for complex production processes, repeated injections, and temperature-sensitive storage. By providing a single injection that lasts up to 12 weeks, Simmbion's approach addresses supply chain disruptions and enhances affordability and accessibility of cell therapies for diverse patient populations. Their adaptable and universally immune compatible systems focus on delivering biological drugs directly in vivo, supporting a patient-centric and outcome-driven healthcare model while minimizing the risks of infections and immune rejection.

Stochastic Research Technologies specializes in delivering fundamental and applied research focused on algorithms, methods, and tools that address challenges in energy, environmental sustainability, molecular modeling, process management, supply chain management, and biomedical engineering. The company develops software solutions aimed at resolving complex issues in the chemical, pharmaceutical, and biomedical sectors. By leveraging modeling, optimization under uncertainty, and process control, Stochastic Research Technologies enables clients across various industries to access effective solutions tailored to their specific needs.

WIndow Therapeutics discovers and develops transformational therapeutics to address critical unmet patient needs in cancer and other life-threatening diseases. They develop breakthrough cancer therapeutics designed to penetrate and permeate into diseased tissue and exert activity specifically against cancer cells and not healthy ones.

InvVax, Inc. is a vaccine development company based in Los Angeles, California, founded in 2012. The company focuses on creating innovative vaccines, with its primary product being a universal influenza vaccine aimed at preventing pandemics. Utilizing a proprietary platform, InvVax's technology analyzes influenza proteins to address virus mutations, thereby enhancing the effectiveness of vaccines. In addition to its work on influenza, InvVax is exploring vaccine candidates for other viral infections, including HIV, Hepatitis B, and Hepatitis C.

Nostopharma specializes in developing treatments for pathologic bone growth, aiming to prevent rare bone diseases and minimize complications from traumatic injuries. The company offers a nanoparticle drug delivery system that addresses soft tissue trauma complications, facilitating the formation of new bone after surgeries, burns, and other traumatic incidents. By enhancing the recovery process, Nostopharma's innovative approach supports healthcare providers in improving clinical outcomes for patients undergoing surgical procedures related to post-traumatic injuries. Additionally, the company's efforts contribute to reducing rehabilitation costs for society.

Isolere Bio is a biotechnology company dedicated to simplifying the purification of biotherapeutics, particularly monoclonal antibodies and Adeno-Associated Viruses (AAV). Co-founded with the aim of enhancing global access to essential drugs, Isolere Bio develops innovative manufacturing technologies that utilize a straightforward Tangential Flow Filtration (TFF) setup. This approach facilitates a seamless transition from laboratory-scale processes to large-scale industrial production, thereby improving efficiency within the bioprocessing industry. As monoclonal antibodies continue to gain prominence as effective therapeutics and important research tools, Isolere Bio's work plays a crucial role in advancing the development of new diagnostics and treatments.

OPOS provides opioid treatment to patients while maintaining regulatory compliance. Their services generate revenue by reducing administrative overhead, reducing prescribing risk, and reducing administrative overhead.

BioSapien is a pre-clinical biotechnology company focused on creating innovative biodegradable implantable products for oncology applications. The company is developing a 3D-printed drug delivery platform that utilizes a biodegradable mesh to deliver active pharmaceutical ingredients (APIs) directly to tumor sites, thereby minimizing systemic side effects associated with traditional therapies. Their flagship product, the MediChip, is designed to administer FDA-approved high-dose systemic therapies in a localized and sustained manner, enhancing the quality of patient care. Current research is focused on applications for pancreatic and lung cancers, with plans to expand the pipeline to include other types such as colorectal, breast, and stomach cancers. By targeting drug delivery directly to cancerous tissues, BioSapien aims to improve treatment efficacy while reducing toxicity for patients.

Clairways provides smart lung monitoring for pharmaceutical clinical trials. Clairways' wearable lung function monitor captures all of the most important respiratory metrics for people suffering from asthma, COPD, CF, or other chronic respiratory diseases.

Felix Biotechnology is working to accelerate the deployment of novel biotherapeutics to manage infectious diseases. Felix Biotechnology's bio-therapeutics targets antibiotic-resistant bacteria to manage infectious diseases precisely and effectively, allowing healthcare professionals to manage urgent microbial challenges in human health.

Niche Biomedical is a platform and therapy development firm that specializes in creating innovative solutions for chronic injuries and disorders that have not responded to traditional pharmacological treatments. The company has developed ANEUVO®, which focuses on addressing these challenging medical conditions. Among its notable innovations is ExaStim®, a non-invasive neuromodulation system that has received FDA Breakthrough Device Designation for the treatment of spinal cord injuries. Additionally, Niche Biomedical is advancing a gastrointestinal therapeutic device aimed at alleviating postoperative ileus and restoring gastrointestinal motility. This device leverages bioelectronic medicine to revolutionize treatment options for various diseases and injuries that are difficult to manage with conventional pharmaceuticals. The company is also capable of developing miniaturized implantable devices that maintain sophisticated functionality, allowing for targeted neuromodulation therapies.

Kodikaz goal is to move from incremental cancer therapies with devastating side effects to durable cures through targeted therapies that can eradicate cancers. Zip-Code™ Technology platform is a first-in-class, cell-specific delivery system that can be used for a broad range of gene therapy applications. Because the Zip-Codes ™ is derived from an endogenous human mechanism it avoids all of the challenges of viral delivery approaches. The Zip-Codes ™ are universally applicable and specific for each cell type.

Nano PharmaSolutions specializes in enhancing the bioavailability of insoluble drugs through its proprietary nanoformulation technology. The company has developed an innovative phase-transition technology platform that significantly improves the solubility of BCS 2 and BCS 4 active pharmaceutical ingredients (APIs) without the need for excipients, which are typically used in traditional processes like spray-dry dispersion and emulsification. By vaporizing the API and depositing it onto a carrier molecule, Nano PharmaSolutions enables the production of nanoparticles that can be processed into various dosage forms. Additionally, the company focuses on delivering neurodegenerative therapeutics directly to the brain via an intranasal route, facilitating a rapid onset of action and enhancing safety profiles. Their pipeline includes treatments for conditions such as Parkinson's disease, peripheral neuropathy, and substance abuse disorders, positioning Nano PharmaSolutions as a key player in the field of nanomedicine.

Ancilia Biosciences focuses on developing engineered bacterial therapies aimed at treating diseases associated with the microbiome. The company specializes in creating virus-resistant live bacterial products that modulate the human microbiome, specifically targeting the viral components within the gut microbiome. By concentrating on healthy gut bacteria and their predatory phages, Ancilia engineers resistant bacterial strains to combat diseases. Its innovative approach includes the development of a new class of live biotherapeutics that allows medical professionals to target specific phages or viruses that induce lysis, with applications in immunology and oncology.

MedChem Partners is a medicinal chemistry CRO that specializes in developing small molecule therapeutics. The company was founded in 2006 and is headquartered in Lexington, Massachusetts.

Paramita Therapeutics is a biotech company established in 2018 and based in San Diego, California. The company is dedicated to developing innovative therapeutics for cancer and infectious diseases. It specializes in efficiently transitioning new therapeutics into clinical settings using a patented, multifunctional chemical platform. This approach allows Paramita Therapeutics to create multivalent drug conjugates derived from recognized and approved molecules with established safety and toxicology profiles. By leveraging its expertise, the company aims to provide patients with access to effective cancer treatments and dual-function therapeutic and vaccine products.

Avior Bio is a clinical-stage, pharmaceutical company developing drugs for distressed neurological conditions. Using its disruptive drug delivery technology – Speedit™ Transmucosal Film Technology – we are positioned to develop products that bring unsurpassed value in efficacy and safety. Avior has an excellent management team, a strong advisory board, supportive partners, dedicated scientists, and knowledgeable clinicians that position us to be successful.

Verantos is the market leader in high-validity real-world evidence for life sciences. By incorporating robust clinical narrative data, artificial intelligence technology, and measured validity, Verantos is the first company to generate research-grade evidence at scale across all therapeutic areas. The Verantos Evidence Platform integrates heterogeneous real-world data sources and generates evidence with the accuracy necessary for market access, HEOR, medical affairs, and regulatory use.

Ballydel Technologies is a research and development company founded in 2018 and based in Newark, Delaware. The company focuses on creating innovative material and technology solutions for various sectors, including space exploration, defense, public health, and societal applications. Ballydel specializes in areas such as nanocomposite design and synthesis, hypersonic materials and manufacturing, as well as pharmaceutical tagging and authentication. Through its expertise, Ballydel aims to assist clients in enhancing their existing products and optimizing their manufacturing processes.

SpheroFill is a drug delivery platform capable of protecting, delivering, and releasing API as solid, liquid, or even gas. From improved compliance by reducing dose frequency to enabling oral formulations that are not possible with present technology, these glass microspheres are the future of drug delivery.

Infini Fluidics develops injectable drug delivery systems intended to treat diseases such as cancer and cardiovascular disease. They provide injectable drug delivery systems at an industrial scale on a portable chip, combining microfluidics with semiconductor technology, enabling patients, healthcare providers, and facilities to get access to lifesaving drugs.

- Next-Gen Fermentors For Next-Gen Business Needs - New Horizon Biotechnologies (NHB) is currently concluding testing of its patented Single Use Horizontal Fermentor system (SUHF™). These studies demonstrate the effectiveness of the system for single-use microbial fermentation and compares and contrasts it with legacy designs currently in use. Microbial fermentation is the basis for the production of a wide range of high value biopharmaceutical products, including antibiotics, vaccines, and therapeutic proteins. NHB intends to deliver production and operational cost savings and efficiencies with its new SUHF™ system that will fundamentally improve the global competitive edge of its users.

Sunthetics specializes in the development of smart electrochemical reactors aimed at enhancing the efficiency of chemical manufacturing, particularly in the pharmaceutical sector. The company's innovative hardware and machine-learning software significantly reduce the time and costs associated with process development, achieving results in one-tenth of the traditional timeframe. This technology not only minimizes energy consumption by 40% but also eliminates the use of toxic chemicals and waste, promoting sustainability. While the primary focus is on pharmaceuticals, Sunthetics' platform technology is adaptable and can be extended to other markets, including agrochemicals and specialty chemicals. By streamlining the development process and enabling the rapid creation of new electrochemical lead molecules, Sunthetics plays a pivotal role in advancing the electrification of the chemical industry.

Quick-Med Technologies, Inc. is a life sciences company dedicated to developing proprietary technologies aimed at infection prevention and control in both medical and consumer healthcare markets. Founded in 1997 and headquartered in Gainesville, Florida, the company specializes in biomedical products and devices with antibacterial applications. Its core technologies include Novel Intrinsically Micro-Bonded Utility Substrate (NIMBUS), a series of advanced polymers with antimicrobial and hemostatic properties; Stay Fresh, a chemical formulation for textiles that provides durable antimicrobial protection; and MultiStat, which comprises patented methods and compounds for skin therapy. Quick-Med serves a diverse range of clients, including government agencies, healthcare providers, and companies in the apparel, textile, and personal care sectors.

VeriSIM Life, Inc. is a biotechnology company based in San Francisco, California, that specializes in developing disease-specific biosimulation models to enhance drug development processes. Founded in 2017, the company utilizes its proprietary BIOiSIM platform to predict the clinical outcomes of new drugs prior to clinical trials, thereby replacing traditional animal testing methods. By employing artificial intelligence, VeriSIM Life aims to improve the accuracy and efficiency of drug development, ultimately contributing to personalized healthcare solutions. Their offerings are tailored to meet the needs of both pre-clinical and clinical programs, focusing on small molecules, large molecules, and viruses to facilitate better treatment options and increase human life expectancy.

Akanocure Pharmaceuticals is a biotechnology company focused on developing innovative anti-cancer chemotherapeutic drugs aimed at treating various forms of cancer. The company is dedicated to finding therapeutic approaches that effectively block the metastatic processes responsible for 90% of cancer-related deaths. By harnessing the expertise of its team throughout the drug discovery and development phases, Akanocure aims to create novel small molecules derived from natural resources. These bio-targeted therapeutics are designed not only to combat cancer but also to alleviate the side effects associated with chemotherapy and other cancer treatments, ultimately improving the quality of life for patients.

Ubiros specializes in the production of food-grade robotic grippers designed for automation in the food and beverage, cosmetics, and pharmaceutical sectors. Their innovative electrically actuated soft grippers, such as the gentle flex module, gentle duo, and gentle pro, enable precise handling of fragile objects without causing damage. These grippers operate without an external air source, which reduces costs, complexity, and noise typically associated with traditional pneumatic or vacuum systems. By utilizing materials like polyurethane, Ubiros provides effective control over gripping force and movement, facilitating the automation of material handling in non-traditional industries.

TEGA was founded to exploit glycoscience-related technologies for the treatment of life-threatening diseases. Glycans, or complex carbohydrates, play important roles in many physiological and pathophysiological processes, but their value as pharmaceutical targets remains underexploited by industry. TEGA specializes in the science of glycans. The TEGA pipeline includes two major programs: glycoside-enhanced lysosomal delivery of proteins and recombinant production of heparan sulfate and heparin. They aim to improve quality of life for patients by enabling delivery of lifesaving treatments for unmet medical needs. Their work is motivated by a commitment to innovation and helping patients. They combine their powerful insights and rigorous scientific methods to help pharmaceutical companies overcome the obstacle of the blood-brain barrier.

Claria Medical is a pre-commercial medical device start-up focused on developing innovative solutions for women's healthcare, specifically targeting unmet needs in gynecologic surgery. The company specializes in creating minimally invasive surgical tools designed to enhance procedures such as hysterectomy and myomectomy. Claria Medical has received recognition for its early achievements, including a “Safer Technologies Designation” from the U.S. Food and Drug Administration. Additionally, the company has secured funding through private investments as well as grants from the National Science Foundation and the National Institutes of Health to support its product development efforts. By providing specialized surgical assistance, Claria Medical aims to improve outcomes for women undergoing these procedures.

StabiLux Biosciences specializes in the production of high-brightness fluorophores aimed at enhancing the performance of reagents used in flow cytometers. The company offers a drop-in platform technology that allows researchers to detect previously undetectable entities while maximizing the capabilities of existing equipment without the need for additional components or software. StabiLux's innovative fluorophores increase brightness across the visible spectrum, significantly improving detection of targeted or cancer cells with minimal noise distortion. This approach enables more effective analysis in various research applications.

AgThera is a biotechnology company focused on discovering, developing, and commercializing innovative antimicrobial medicines for infectious diseases. The company specializes in advanced probiotics that are engineered to effectively eliminate pathogens, including antibiotic-resistant bacteria. AgThera’s platform utilizes probiotic bacteria that express and secrete antimicrobial peptides, providing a novel approach to combatting infections. The company's research and development efforts are supported by grants from the US National Science Foundation and the US Department of Agriculture, enabling the advancement of its AI-enhanced R&D program. AgThera aims to facilitate the development of drugs for both human and livestock use, addressing the growing concern of antibiotic resistance in various medical and agricultural settings.

VerImmune, based in Baltimore, Maryland, is an immuno-oncology company focused on developing innovative cancer therapies through its proprietary technology, Anti-tumor Immune Redirection Virus-inspired Particles (AIR-ViPs). This unique approach aims to harness pre-existing immune memory from pathogens or childhood vaccines to target and redirect the immune system toward tumors. By doing so, VerImmune seeks to address significant challenges in cancer treatment, particularly for patients with limited options or those who have developed resistance to conventional therapies. The company's strategy promises to offer low toxicity and sustained benefits across a diverse range of cancer types, potentially transforming the treatment landscape for those with difficult-to-treat malignancies.

New Equilibrium Biosciences is focused on developing therapeutic drugs aimed at treating cancer and neurodegenerative diseases. The company employs a unique approach that integrates artificial intelligence with quantum chemistry to enhance biophysical experiments. This innovative platform specializes in the research and development of therapeutics that target intrinsically disordered proteins (IDPs), which are often implicated in various neurodegenerative disorders. By utilizing IDP-specific compound libraries, New Equilibrium Biosciences seeks to identify and exploit transient binding pockets on these proteins, facilitating the discovery of lead drug candidates. This approach aims to improve medical procedures and ultimately contribute to advancements in healthcare.

Prime Labs is a company focused on enhancing drug discovery through its cloud-based software platform, which specializes in mass spectrometry data processing, analysis, reporting, and visualization. The software is designed to support a variety of instruments and workflows, enabling scientists to conduct experiments with greater accuracy and efficiency. By streamlining the data processing experience, Prime Labs offers a user-friendly solution that minimizes the complexity typically associated with such tasks, allowing researchers to focus on their work with minimal training or installation requirements. This innovative approach facilitates a broader range of experiments in a shorter time frame, ultimately contributing to advancements in medical research and drug development.

Caza Health is a biotech company specializing in the microbiome, immunology, and oncology. The company was founded in 2019 and is headquartered in Earlysville, Virginia.

Intact Therapeutics is a biotechnology company based in Belmont, California, founded in 2015. The company focuses on developing a thermosensitive drug delivery platform, specifically smart gels designed for the treatment of gastrointestinal disorders, including ulcerative colitis. Their proprietary gel technology remains in a liquid state at room temperature, transforming into a mucoadhesive gel at body temperature. This innovative approach allows for targeted drug delivery, providing localized concentrations of medication while minimizing systemic exposure. The gel's design enhances drug retention, efficacy, and patient comfort, offering a painless healing option for individuals suffering from inflammatory bowel diseases.

VeraMorph is a pharmaceutical company established in 2017 and located in Mansfield, Massachusetts. The company specializes in developing an innovative oral drug delivery technology centered around proprietary oral hydrogel tablets. This technology is designed to enhance drug stability, expedite dissolution rates, and maintain prolonged high saturation levels, allowing for higher drug loading compared to existing formulations. By providing contract manufacturing and formulation services, VeraMorph aims to assist pharmaceutical companies in improving the performance of their products while reducing both costs and the time required to bring new drugs to market.

Proteios Technology provides scientists with the ability to obtain biopharmaceuticals at a low cost. The company was founded in 2015 and is headquartered in Issaquah, Washington.

Oscillo Biosciences focuses on developing innovative pharmacological treatments for Alzheimer's disease and related disorders. The company has conducted studies to assess the impact of music and multisensory stimulation on brain activity in adults. Oscillo Biosciences creates a prescription medical device and a digital therapeutic that work in tandem to restore healthy brain function in patients experiencing mild cognitive impairment and Alzheimer's disease. Their approach is grounded in the understanding that brain rhythms essential for memory and cognition are disrupted in these patients. Additionally, Oscillo Biosciences develops human-centered technologies aimed at rehabilitating individuals with language, cognitive, and motor impairments, utilizing rhythmic behaviors associated with speech, music, and movement to create effective therapies.

A-Alpha Bio, Inc. is a biotechnology company based in Seattle, Washington, established in 2017. The company specializes in synthetic biology, offering a platform known as AlphaSeq, which assists pharmaceutical companies in the development of drugs that interact with multiple targets. A-Alpha Bio provides cell-based tools for high-throughput and quantitative measurements of protein interactions, facilitating target discovery, library screening, and preclinical drug characterization. Its proprietary technology enables the mapping of protein-protein interactions at a large scale, allowing for the identification and quantification of interactions among thousands of protein pairs simultaneously. By delivering detailed maps of these interactions, A-Alpha Bio helps researchers identify potential drug targets and understand disease mechanisms, thereby streamlining the therapeutic discovery process and improving the efficiency of drug development. The company comprises a team of experts in synthetic biology, structural biology, and next-generation sequencing, focused on overcoming challenges in the drug development pipeline.

Inso Biosciences is an early-stage biotechnology company focused on developing innovative hardware platforms and tools for genomic sample handling. Utilizing patented microfluidic technology originally created at Cornell University, the company specializes in high-efficiency processing of cellular material. Inso Biosciences aims to enhance applications in long-read DNA extraction, multiomic sample processing, and pathogen surveillance. Their platform facilitates the separation and isolation of cellular components, thereby supporting healthcare and biotech companies in their biological sample preparation needs.

Akanocure Pharmaceuticals is a biotechnology company focused on developing innovative anti-cancer chemotherapeutic drugs aimed at treating various forms of cancer. The company is dedicated to finding therapeutic approaches that effectively block the metastatic processes responsible for 90% of cancer-related deaths. By harnessing the expertise of its team throughout the drug discovery and development phases, Akanocure aims to create novel small molecules derived from natural resources. These bio-targeted therapeutics are designed not only to combat cancer but also to alleviate the side effects associated with chemotherapy and other cancer treatments, ultimately improving the quality of life for patients.

IDEM Systems provides drug testing kits and drug intelligence technology based on academic research. The testing system uses a novel chemical method to identify drugs, including heroin, other opiates, fentanyl and its derivatives, cocaine, and others. Among the devices are a handheld spectrometer, a sample pen, and a mobile application that allows users to access a proprietary database to identify suspect substances on-site accurately.

QCMedchain is a startup focused on transforming the pharmaceutical supply chain through a blockchain-based platform. Funded by the National Science Foundation, the company aims to enhance the safety and efficiency of medicine distribution. Its platform allows for real-time tracking of medications at the package level, ensuring that each product's authenticity is verified and recorded immutably on the network. This capability enables pharmaceutical companies and government entities to monitor the journey of medicines from manufacturing to the end consumer, thereby improving accountability and reducing the risks associated with counterfeit drugs.

Capienda Biotech focuses on enhancing the drug discovery process by providing an innovative biotechnology platform that significantly reduces the time and cost associated with developing new medicines. By addressing a critical bottleneck in drug discovery, Capienda's advanced bioanalytical system allows for faster and more efficient designs of small molecules, which results in higher quality drugs entering clinical trials. Their high-throughput kinetics system offers a throughput 48 times greater than traditional methods, eliminating the need for specialist scientists. The company's offerings include a laboratory instrument system and assay chemicals, creating a recurring revenue model that supports ongoing research and development efforts.

Niche Biomedical is a platform and therapy development firm that specializes in creating innovative solutions for chronic injuries and disorders that have not responded to traditional pharmacological treatments. The company has developed ANEUVO®, which focuses on addressing these challenging medical conditions. Among its notable innovations is ExaStim®, a non-invasive neuromodulation system that has received FDA Breakthrough Device Designation for the treatment of spinal cord injuries. Additionally, Niche Biomedical is advancing a gastrointestinal therapeutic device aimed at alleviating postoperative ileus and restoring gastrointestinal motility. This device leverages bioelectronic medicine to revolutionize treatment options for various diseases and injuries that are difficult to manage with conventional pharmaceuticals. The company is also capable of developing miniaturized implantable devices that maintain sophisticated functionality, allowing for targeted neuromodulation therapies.

Inso Biosciences is an early-stage biotechnology company focused on developing innovative hardware platforms and tools for genomic sample handling. Utilizing patented microfluidic technology originally created at Cornell University, the company specializes in high-efficiency processing of cellular material. Inso Biosciences aims to enhance applications in long-read DNA extraction, multiomic sample processing, and pathogen surveillance. Their platform facilitates the separation and isolation of cellular components, thereby supporting healthcare and biotech companies in their biological sample preparation needs.

Prime Labs is a company focused on enhancing drug discovery through its cloud-based software platform, which specializes in mass spectrometry data processing, analysis, reporting, and visualization. The software is designed to support a variety of instruments and workflows, enabling scientists to conduct experiments with greater accuracy and efficiency. By streamlining the data processing experience, Prime Labs offers a user-friendly solution that minimizes the complexity typically associated with such tasks, allowing researchers to focus on their work with minimal training or installation requirements. This innovative approach facilitates a broader range of experiments in a shorter time frame, ultimately contributing to advancements in medical research and drug development.

Senseer Health, founded in 2017, focuses on addressing the chronic disease market by developing Smart Medical Device Therapies for managing various chronic conditions, which affect a significant portion of older adults. The company's innovations began with patented microsensors that monitor implantable devices for patients with hydrocephalus, renal, and cardiovascular diseases. To enhance the effectiveness of these microsensor-enabled devices, Senseer has incorporated advanced wearable and ambient sensor technologies. The integration of these multi-modal sensor technologies with an IoT software platform allows for the utilization of proprietary data sets and predictive analytics. This comprehensive approach provides healthcare providers with tools for remote monitoring and timely interventions, ultimately aiming to improve the quality of life for individuals with chronic conditions while reducing costs and enhancing patient safety.

3D Health Solutions develops a novel 3D canine organoid model to study oral drug permeability and metabolism. The company is based in Ames, Iowa.

Sasya is a biotech company that produces functional supplements. Its products are applicable across all species including humans, companion animals, and fish.

Azitra is a clinical-stage medical dermatology company that leverages extensive scientific knowledge about the skin microbiome to discover and develop novel products for the treatment of adverse skin conditions and diseases.The Company’s technology platform, developed in collaboration with scientists at Yale University and the Jackson Laboratory, is based on a proprietary strain of the natural commensal bacteria Staphylococcus epidermidis.

Zebra Analytix, Inc. specializes in the development and commercialization of miniature gas chromatography systems utilizing microelectromechanical systems technology licensed from Virginia Tech University. Founded in 2017 and headquartered in Fayetteville, Arkansas, the company offers products such as the Zebra-GC Model L and Modular Zebra-GC Model M, along with micro pre-concentrators. These systems are designed to provide rapid and portable analysis of volatile compounds, making them suitable for applications in various industries including food and beverage quality control, environmental monitoring, pharmaceuticals, and energy sectors. Additionally, Zebra Analytix offers services such as column refurbishment and custom designs tailored for specific research needs. The company's innovative technology features microfabricated chips that allow for multi-channel separations, significantly enhancing the efficiency and versatility of gas analysis.

Advaita Corporation is a bioinformatics company founded in 2005 and based in Plymouth, Michigan. It specializes in developing software tools designed for the research and pharmaceutical industries, focusing on the analysis of gene expression data. One of its key products, Pathway-Guide, assists biologists and drug researchers in interpreting the extensive data generated from gene-expression experiments. The company also offers consulting services, which include pathway analysis, biological model construction, biomarker identification and prioritization, expression data interpretation, and data interpretation training. Advaita's software integrates multi-omic data from a systems biology perspective, catering to the needs of investigators, core facilities, and enterprise bioinformatics teams.

SpIntellx, Inc. is a computational and systems pathology company based in Pittsburgh, Pennsylvania, specializing in spatial intelligence software products for cancer diagnosis. Established in 2017, the company offers innovative solutions such as SpIntellx, which analyzes image data sets from various imaging platforms and reagent types, enabling precise analysis of pathology tissue sections. Additionally, SpIntellx provides HistoMapr, a computational guide for pathologists, and TumorMapr, which examines the spatial interactions of biomarkers within whole slide images using multiplexed fluorescence. By leveraging unbiased spatial analytics powered by explainable AI, SpIntellx aims to enhance the understanding of complex cancer biology, contributing to advancements in medicine and research across drug development, diagnostics, and treatment pipelines.

TEGA was founded to exploit glycoscience-related technologies for the treatment of life-threatening diseases. Glycans, or complex carbohydrates, play important roles in many physiological and pathophysiological processes, but their value as pharmaceutical targets remains underexploited by industry. TEGA specializes in the science of glycans. The TEGA pipeline includes two major programs: glycoside-enhanced lysosomal delivery of proteins and recombinant production of heparan sulfate and heparin. They aim to improve quality of life for patients by enabling delivery of lifesaving treatments for unmet medical needs. Their work is motivated by a commitment to innovation and helping patients. They combine their powerful insights and rigorous scientific methods to help pharmaceutical companies overcome the obstacle of the blood-brain barrier.

Trilo Therapeutics, based in San Francisco and founded by experienced professionals in the biotech and pharmaceutical sectors, focuses on developing innovative peptide-drug conjugates (PDCs) to overcome the limitations of current antibody-drug conjugates (ADCs). The company employs macrocyclic D-amino acid peptides to replace the antibody component, resulting in superior tumor penetration and reduced toxicity compared to traditional L-amino acid peptide-drug conjugates. Trilo's conjugates are designed to be compatible with clinically validated payloads and radionuclides, facilitating new treatment modalities through a "fast in/fast out" mechanism. Additionally, Trilo is engaged in creating novel inhibitors of protein interactions, aiming to target disease-causing proteins for the treatment of cancer, autoimmune disorders, and infectious diseases. This dual focus on peptide-based therapies and protein interaction inhibitors positions Trilo Therapeutics as a leader in developing effective treatments for severe medical conditions.

Aracari Biosciences specializes in developing advanced 3D Vascularized Micro-Organ platforms aimed at improving the drug discovery process. These platforms enhance the biological authenticity of pre-clinical testing by allowing for real-time imaging of vessel morphology, which facilitates the investigation of lead compound efficacy against tumors in a three-dimensional environment. The technology is designed to adapt to various physiological conditions and can be perfused with fluorophore-tagged dextrans of different molecular weights. This capability assists pharmaceutical companies in making informed decisions and accelerates the development of new drugs.

VaxForm offers vaccine product consultation and contract development services. The company was founded in 2010 and is headquartered in Lehigh Valley, Pennsylvania.

GMJ Technologies, founded in 2018 and based in Seattle, Washington, specializes in developing microanalytical technologies for biopharmaceutical and biomedical applications. The company focuses on creating robust analytical tools and integrated technologies that enhance proteomics and protein-based biologics workflows. By streamlining research, development, and manufacturing processes, GMJ Technologies aims to advance the capabilities of analytical methodologies in the life sciences sector.

Rumi Scientific is a research-oriented company focused on developing innovative medications and treatments for genetic disorders affecting the central nervous system, particularly Huntington's Disease. The company utilizes a proprietary human organoid platform that simulates human development in vitro, integrating gene editing techniques with multi-cellular self-organization to create defined diseased embryonic tissues. This advanced platform facilitates drug discovery and high-throughput screening, leveraging artificial intelligence to identify potential treatments. By emphasizing synthetic human embryology in both healthy and diseased contexts, Rumi Scientific aims to advance therapeutic options for numerous genetic conditions that currently lack effective cures. The company's approach combines single-cell, time-lapse imaging with customized analytic tools, resulting in a more efficient and cost-effective drug development process that enhances treatment success rates and outcomes for patients.

BioInfoExperts specializes in comprehensive molecular surveillance services aimed at understanding infectious disease dynamics and monitoring pathogens. The company offers a range of services, including genomic sequencing, RNA and DNA extraction, data analytics, and cloud-based data visualization. These services are designed to support clients in researching and developing various diagnostic tests while providing essential laboratory capabilities. Through its expertise, BioInfoExperts contributes to advancements in the field of infectious disease management and pathogen tracking.

Dynalene Inc. is a company based in Whitehall, Pennsylvania, specializing in the development, manufacturing, and distribution of industrial heat transfer fluids and coolants suitable for ultra-low temperature cryogenic applications. The product range includes glycols, brines, potassium formate, calcium chloride, and high-performance coolants, alongside nanodiamond products and functionalized nano-materials. These offerings cater to various industries, including fuel cells, solar and geothermal applications, HVAC, supermarket refrigeration, plastics manufacturing, and pharmaceuticals. Additionally, Dynalene provides lab services that encompass thermal and physical analysis, chemical testing, and material and corrosion testing. The company, founded in 1993, also sells its products through an online store, ensuring accessibility for its clients.

Elektrofi is a preclinical-stage company based in Boston, Massachusetts, focused on advancing drug delivery methods to enhance patient experiences. Established in 2016, the company has developed a formulation system capable of processing a diverse array of therapeutic molecules, including large and complex proteins such as monoclonal antibodies, bispecifics, and fusion proteins. Its innovative technology aims to improve subcutaneous administration, allowing drug manufacturers to create breakthrough therapies that empower patients with more control over how they receive essential medications.

A-Alpha Bio, Inc. is a biotechnology company based in Seattle, Washington, established in 2017. The company specializes in synthetic biology, offering a platform known as AlphaSeq, which assists pharmaceutical companies in the development of drugs that interact with multiple targets. A-Alpha Bio provides cell-based tools for high-throughput and quantitative measurements of protein interactions, facilitating target discovery, library screening, and preclinical drug characterization. Its proprietary technology enables the mapping of protein-protein interactions at a large scale, allowing for the identification and quantification of interactions among thousands of protein pairs simultaneously. By delivering detailed maps of these interactions, A-Alpha Bio helps researchers identify potential drug targets and understand disease mechanisms, thereby streamlining the therapeutic discovery process and improving the efficiency of drug development. The company comprises a team of experts in synthetic biology, structural biology, and next-generation sequencing, focused on overcoming challenges in the drug development pipeline.

Plumb Pharmaceuticals specializes in the development of super-extended-release formulations of weak-base, small-molecule pharmaceuticals through innovative quantload technologies. The company's proprietary lipid nanoparticle technology allows for the production of a diverse range of medications, including stimulants for ADHD, anti-HIV drugs, antibiotics, antipsychotics, cancer chemotherapeutic agents, antihistamines, and analgesics. By enhancing the efficacy and delivery of these pharmaceuticals, Plumb Pharmaceuticals aims to contribute significantly to the healthcare sector and improve overall health outcomes.

Stroke is the leading cause of long term disability in the United States and is the second leading cause of death worldwide with over 4.4 million deaths a year. It affects over 700,000 patients every year in the United States alone.

Verantos is the market leader in high-validity real-world evidence for life sciences. By incorporating robust clinical narrative data, artificial intelligence technology, and measured validity, Verantos is the first company to generate research-grade evidence at scale across all therapeutic areas. The Verantos Evidence Platform integrates heterogeneous real-world data sources and generates evidence with the accuracy necessary for market access, HEOR, medical affairs, and regulatory use.

IonDX is a bioanalytical instrumentation company commercializing an advanced system to analyze biologic drugs. It leverages the expertise of founding members who have over 40 years of experience developing analytical instrumentation for biomacromolecules and nanomaterials. The company's innovative and patented ion mobility technology aims to help scientists analyze the higher order structure of proteins and biotherapeutics in a high throughput manner.

Proteios Technology provides scientists with the ability to obtain biopharmaceuticals at a low cost. The company was founded in 2015 and is headquartered in Issaquah, Washington.

Hinge Bio is a biotechnology company that specializes in leveraging its proprietary Flex-Hinge antibody platform to develop bispecific and multispecific antibodies. It features chemical ligation process technology that enables the production of therapeutic candidates with orders-of-magnitude improved affinity and specificity. The company was founded in 2015 and headquartered in Burlingame, California.

Akanocure Pharmaceuticals is a biotechnology company focused on developing innovative anti-cancer chemotherapeutic drugs aimed at treating various forms of cancer. The company is dedicated to finding therapeutic approaches that effectively block the metastatic processes responsible for 90% of cancer-related deaths. By harnessing the expertise of its team throughout the drug discovery and development phases, Akanocure aims to create novel small molecules derived from natural resources. These bio-targeted therapeutics are designed not only to combat cancer but also to alleviate the side effects associated with chemotherapy and other cancer treatments, ultimately improving the quality of life for patients.

At BioNanoTech, we are on a mission to save lives. We have solved a significant hurdle for drug innovation & discovery. Our revolutionary size-invariant, ultra-high purity, and high-yield protein and antibody purification technology platform unlock the $265B market. We create new pathways for drug and vaccine discovery, production, and biological testing at a fraction of the previous lifetime costs. Our technology empowers the pharmaceutical and scientific community to expand their current production and revisit previous low-yield lines at the production scale, exposing new opportunities and turning waste into revenue so that no cure is left behind.

Intabio, Inc. is a biopharmaceutical analytics company founded in 2015 and based in Newark, California. The company specializes in developing innovative analytical solutions designed to enhance the efficiency of biopharmaceutical development and manufacturing. Intabio's key product, the Blaze system, is a bench-top instrument that utilizes a microfluidic chip and reagent kit to perform separation, quantitation, and molecular mass identity analysis. This system is particularly valuable for identifying unwanted structural modifications in intact biotherapeutic proteins. Intabio also offers a microfluidic platform that enables real-time characterization of protein isoforms, aiding in the identification of specific modifications. By providing early product quality characterization, Intabio's technologies significantly improve throughput and reduce costs compared to traditional methods, facilitating the comprehensive analysis of antibody and protein biopharmaceuticals in development.

Glyscend Therapeutics is focused on developing innovative treatments for type 2 diabetes, drawing inspiration from the metabolic benefits observed in bariatric surgery. The company has created a non-invasive, orally ingestible intestinal coating designed to replicate the effects of surgery by preventing stimulation of the duodenal mucosa and inhibiting crucial neurohormonal pathways in the proximal gut. This novel approach aims to provide patients with effective glucose control while minimizing side effects such as weight gain and hypoglycemia. Glyscend also seeks to equip endocrinologists and primary care physicians with advanced tools to treat diabetes more effectively, rather than merely managing the condition. Founded in 2014 by Ashish Nimgaonkar, Michael Parlato, and Pratik Patel, Glyscend is committed to enhancing the care pathway for individuals living with type 2 diabetes.

StabiLux Biosciences specializes in the production of high-brightness fluorophores aimed at enhancing the performance of reagents used in flow cytometers. The company offers a drop-in platform technology that allows researchers to detect previously undetectable entities while maximizing the capabilities of existing equipment without the need for additional components or software. StabiLux's innovative fluorophores increase brightness across the visible spectrum, significantly improving detection of targeted or cancer cells with minimal noise distortion. This approach enables more effective analysis in various research applications.

AgThera is a biotechnology company focused on discovering, developing, and commercializing innovative antimicrobial medicines for infectious diseases. The company specializes in advanced probiotics that are engineered to effectively eliminate pathogens, including antibiotic-resistant bacteria. AgThera’s platform utilizes probiotic bacteria that express and secrete antimicrobial peptides, providing a novel approach to combatting infections. The company's research and development efforts are supported by grants from the US National Science Foundation and the US Department of Agriculture, enabling the advancement of its AI-enhanced R&D program. AgThera aims to facilitate the development of drugs for both human and livestock use, addressing the growing concern of antibiotic resistance in various medical and agricultural settings.

Manus Bio Inc. specializes in recreating plant processes within microorganisms to produce natural ingredients through advanced fermentation technology. Founded in 2011 and based in Cambridge, Massachusetts, the company focuses on converting sugar sources into a variety of applications, including flavors, fragrances, food ingredients, cosmetics, vitamins, pharmaceuticals, and agricultural chemicals. By integrating metabolic engineering, protein engineering, and systems biology, Manus Bio develops microbes that efficiently manufacture complex and bioactive natural products. The company operates manufacturing facilities in Cambridge and Augusta, Georgia, and has established a strategic partnership with BBGI Public Company Limited. Formerly known as Manus Biosynthesis, Inc., the company adopted its current name in June 2018.

iVeena is a biopharmaceutical company focused on developing innovative treatments for ophthalmic diseases. Founded in 2006 by Bala Ambati and headquartered in Salt Lake City, Utah, iVeena is advancing five products that are currently in late pre-clinical and research stages. The company's targeted indications include post-surgery cataract inflammation, macular degeneration (Wet AMD), diabetic retinopathy, and glaucoma. iVeena utilizes proprietary drug delivery systems, including methods that allow for treatment directly from the lens capsule, which enhances the effectiveness of therapies for corneal diseases and myopic conditions.

CGeneTech is being developed for the production and distribution of synthetic DNA purification kits for use in research and medicine. They provide services including selling ODN purification kits, custom synthesis, lead optimization, and library design and synthesis.

Arch Innotek, LLC is a biotechnology company based in St. Louis, Missouri, focused on engineering microorganisms to produce natural ingredients that promote health for both humans and animals. Established in 2013, the company specializes in the fermentation of yeast to generate natural carotenoid antioxidants and other high-value molecules for the food, feed, pharmaceutical, and cosmetics industries. Arch Innotek employs sustainable and cost-effective fermentation processes to develop innovative technologies that provide healthier alternatives for consumers. Additionally, the company offers a range of scientific services, including HPLC analysis, LC-MS analysis, protein purification, and molecular cloning, to support its research and development efforts.

Advaita Corporation is a bioinformatics company founded in 2005 and based in Plymouth, Michigan. It specializes in developing software tools designed for the research and pharmaceutical industries, focusing on the analysis of gene expression data. One of its key products, Pathway-Guide, assists biologists and drug researchers in interpreting the extensive data generated from gene-expression experiments. The company also offers consulting services, which include pathway analysis, biological model construction, biomarker identification and prioritization, expression data interpretation, and data interpretation training. Advaita's software integrates multi-omic data from a systems biology perspective, catering to the needs of investigators, core facilities, and enterprise bioinformatics teams.

Pinpoint Pharma, a healthcare company, is changing veterinary medicine by printing custom medicine for pets on demand.

MAA Laboratories is a pharmaceutical company specializing in the development of innovative nanotechnology for drug delivery. Founded in 2013 and headquartered in Durham, North Carolina, the company focuses on creating small, water-soluble drug molecules using its proprietary NanoCont technology. This technology enables the formulation of oral nanomedicines that address various challenges related to drug delivery and solubility. MAA Laboratories is actively engaged in developing medications for conditions such as Alzheimer’s disease and migraines, serving clients in the pharmaceutical industry with its advanced drug development platform.

Shasqi, Inc. is a biopharmaceutical company based in San Francisco, California, founded in 2018. It specializes in the development of a unique platform known as CAPAC (Click Activated Protodrugs Against Cancer), which utilizes click chemistry for localized drug activation. This innovative approach allows for the activation of chemotherapeutic agents directly at tumor sites, thereby concentrating the drug's effects where they are most needed while minimizing systemic toxicity. The technology involves injecting a polymer gel that contains a click chemistry reagent in the tumor area, which subsequently activates a systemically administered protodrug when they interact. Shasqi's platform has demonstrated efficacy in human trials, indicating its potential to enhance cancer treatment outcomes and paving the way for future advancements in click-chemistry-based therapies.

Data2Discovery is an IT consulting platform specializing in healthcare data analytics, particularly within drug discovery, disaster medicine, and food science. The company focuses on extracting valuable insights from complex and diverse datasets using advanced technologies, including scalable graph technologies and machine learning. With a patent-pending approach, Data2Discovery combines public and proprietary data sources along with graph mining capabilities to effectively link and map data. Their services encompass data science and healthcare solutions, ensuring that client inquiries are promptly addressed through various communication channels such as phone, email, and online applications. The platform is designed to help users efficiently obtain the results they need in their respective fields.

Histogen Inc. is a regenerative medicine company based in San Diego, California, that specializes in developing therapies using products derived from cells cultivated under simulated embryonic conditions. The company utilizes its innovative platform to produce human multipotent cell conditioned media and human extracellular matrix materials, which aim to replace and regenerate tissues in the body. Histogen's main focus is on stimulating patients' own stem cells through a complex of multipotent human proteins that promote stem cell growth and differentiation. Among its notable product candidates are HST-003 for joint cartilage repair and HST-004 for spinal disc repair. Additionally, Histogen is advancing a pipeline of small molecule inhibitors targeting infectious and inflammatory diseases, addressing significant gaps in therapeutic options within multi-billion dollar global markets.

ConsortiEX Inc. is a health care technology company that serves pharmacies by providing systems and services for the ordering, distribution, and tracking of pharmaceuticals within hospitals in the United States. Founded in 2013 and headquartered in Milwaukee, Wisconsin, ConsortiEX offers Assure-Trak, an enterprise resource planning system designed to facilitate the collection, integration, management, and sharing of pharmacy information, particularly for the compounding of sterile products. The company also delivers a range of health care information technology services, which include pedigree management, IV workflow management, inventory and logistics management, and quality management reporting. Additionally, ConsortiEX provides compliance services related to the Drug Supply Chain Security Act as well as e-commerce order management services to support the compounding pharmacy needs of its member institutions and affiliates.

enEvolv, Inc. specializes in engineering and licensing microorganisms, including bacteria, yeast, and algae, to produce chemicals, enzymes, and small molecules for various industries such as specialty chemicals, food, energy, personal care, and pharmaceuticals. Founded in 2011 and based in Boston, Massachusetts, enEvolv addresses the growing global demand for essential resources due to population growth and economic development. The company collaborates with other businesses to engineer novel microorganisms and enhance existing strains, aiming to increase production yield and product quality. Utilizing its proprietary genome engineering platform, which employs Multiplex Automated Genome Engineering (MAGE) technology developed at Harvard, enEvolv accelerates the evolution of living cells, offering significant advantages in speed, cost, and engineering capabilities. As of March 2020, enEvolv operates as a subsidiary of Zymergen, Inc.

BioInfoExperts specializes in comprehensive molecular surveillance services aimed at understanding infectious disease dynamics and monitoring pathogens. The company offers a range of services, including genomic sequencing, RNA and DNA extraction, data analytics, and cloud-based data visualization. These services are designed to support clients in researching and developing various diagnostic tests while providing essential laboratory capabilities. Through its expertise, BioInfoExperts contributes to advancements in the field of infectious disease management and pathogen tracking.

Niche Biomedical is a platform and therapy development firm that specializes in creating innovative solutions for chronic injuries and disorders that have not responded to traditional pharmacological treatments. The company has developed ANEUVO®, which focuses on addressing these challenging medical conditions. Among its notable innovations is ExaStim®, a non-invasive neuromodulation system that has received FDA Breakthrough Device Designation for the treatment of spinal cord injuries. Additionally, Niche Biomedical is advancing a gastrointestinal therapeutic device aimed at alleviating postoperative ileus and restoring gastrointestinal motility. This device leverages bioelectronic medicine to revolutionize treatment options for various diseases and injuries that are difficult to manage with conventional pharmaceuticals. The company is also capable of developing miniaturized implantable devices that maintain sophisticated functionality, allowing for targeted neuromodulation therapies.

Macromoltek does computational drug discovery for pharma companies, focusing on antibodies for therapeutics and diagnostics. This mother-daughter team’s approach aims to make research for everything from flu to cancer treatments an order of magnitude faster. With an accelerated process to discover antibodies, medical researchers can (1) craft targeted treatment plans for previously undruggable targets and (2) overcome patients’ drug resistance, a major challenge when treating diseases caused by bacteria, viruses, and parasites.

AxoSim, Inc. is a biotechnology company based in New Orleans, Louisiana, specializing in the development of innovative platforms for neurological drug discovery. Founded in 2014, AxoSim focuses on accelerating the drug development process by providing advanced in vitro models that mimic the human nervous system. Its key technologies include Nerve-on-a-Chip, which predicts clinical neurotoxicity and models human neurodegenerative diseases, and NerveSim, which features human-relevant Schwann cell myelination and electrical metrics. Additionally, AxoSim offers BrainSim, a platform that supports oligodendrocyte myelination for testing in neurotoxicity. By creating 3D cell-based models that replicate the structure and function of nerve tissue, AxoSim aims to enhance the efficiency of pharmaceutical research while reducing reliance on traditional animal testing methods.